Icatibant

Background

Icatibant is a synthetic decapeptide and selective bradykinin B2 receptor antagonist developed from the bradykinin sequence with multiple non‑natural amino acid substitutions to confer metabolic stability and high receptor affinity.[12][15] It is also known as HOE‑140 and is marketed as Firazyr in prefilled syringes for subcutaneous administration.[11][15] The peptide sequence (D‑Arg‑[Hyp3,Thi5,D‑Tic7,Oic8]‑bradykinin) was engineered in the 1980s–1990s in medicinal chemistry programs targeting kinin receptors for cardiovascular and inflammatory indications.[12][15]

Hereditary angioedema (HAE) due to C1‑inhibitor deficiency or dysfunction is characterized by recurrent, self‑limiting but potentially life‑threatening angioedema attacks of the skin, gastrointestinal tract, or upper airway.[11] Excessive generation of bradykinin and signaling via bradykinin B2 receptors is recognized as the key pathogenic pathway in HAE.[11][14] Icatibant was developed as a targeted therapy to interrupt this pathway.

Icatibant received orphan drug designation and was approved in the European Union in 2008 and subsequently by the US Food and Drug Administration (FDA) in 2011 for treatment of acute attacks of HAE in adults.[11][13][15] It has since become a core on‑demand therapy for HAE attacks and has been investigated off‑label for other bradykinin‑mediated angioedema, including angiotensin‑converting enzyme inhibitor (ACEI)–induced angioedema and acquired C1 inhibitor deficiency.[5][6][8]

Mechanism of action

Icatibant is a high‑affinity, competitive antagonist of the human bradykinin B2 receptor, a G protein‑coupled receptor constitutively expressed on vascular endothelial and smooth muscle cells.[12][13][15] Bradykinin binding to B2 receptors increases endothelial nitric oxide and prostacyclin production and disrupts endothelial junctions, leading to vasodilation, increased vascular permeability, and tissue edema.[11][12]

In a controlled human forearm blood‑flow study in eight healthy volunteers, intravenous icatibant at doses of 20–100 µg/kg produced a dose‑dependent inhibition of bradykinin‑induced vasodilation, confirming effective B2 receptor blockade in vivo.[12] Icatibant does not require enzymatic activation and directly competes with bradykinin at B2 receptors, without significant activity at B1 receptors.[13][15]

In HAE due to C1‑inhibitor deficiency, dysregulated plasma kallikrein activity leads to excessive cleavage of high‑molecular‑weight kininogen and overproduction of bradykinin.[11][14] By antagonizing B2 receptors, icatibant interrupts this final common effector pathway, reducing microvascular leakage and resolving angioedema attacks.[11][14][15]

Pharmacokinetically, icatibant is administered subcutaneously, with rapid absorption and a relatively short terminal half‑life on the order of several hours; it is degraded by ubiquitous peptidases rather than via a single organ metabolic pathway.[11][15] The peptide nature of the molecule limits oral bioavailability, necessitating parenteral administration.

Evidence summary

Pivotal hereditary angioedema trials

The principal efficacy data derive from the For Angioedema Subcutaneous Treatment (FAST) clinical trial program.

• FAST‑1 and FAST‑2 (Hereditary Angioedema; N Engl J Med 2010): Two double‑blind, randomized, multicenter Phase III trials evaluated subcutaneous icatibant 30 mg for acute cutaneous or abdominal HAE attacks.[14] FAST‑1 (United States) compared icatibant with placebo in 56 patients (74 attacks), while FAST‑2 (Europe) compared icatibant with oral tranexamic acid in 74 patients (77 attacks).[14]

  • Primary outcome (time to onset of symptom relief): In FAST‑1, median time to symptom relief was 2.5 h with icatibant vs 4.6 h with placebo; the difference did not reach the prespecified statistical significance for the primary endpoint, although secondary endpoints favored icatibant.[14] In FAST‑2, median time to onset of symptom relief was 2.0 h with icatibant vs 12.0 h with tranexamic acid (statistically significant).[14]
  • Secondary outcomes included time to almost complete relief, patient‑reported global response, and need for rescue medication; these generally supported more rapid and more complete resolution with icatibant.[14]

• FAST‑3 (Hereditary Angioedema; extension and open‑label data): Open‑label extension data and additional randomized experience confirmed consistency of effect across multiple attacks and attack locations, with median times to symptom improvement generally in the 1.5–3 h range and acceptable safety.[11][14]

A comprehensive review of HAE epidemiology and icatibant clinical data reports that single 30 mg subcutaneous doses produced rapid and clinically meaningful improvements in cutaneous, abdominal, and laryngeal attacks in Phase III trials and long‑term follow‑up cohorts.[4][11] Observational studies have also reported successful self‑administration in home settings, with reduced time to treatment and improved patient autonomy.[1][2][11]

Other bradykinin‑mediated angioedema

Evidence outside HAE is more limited and largely consists of small series and case reports.

• ACE inhibitor–induced angioedema: A case report described a 75‑year‑old woman with severe ACEI‑induced tongue and lip angioedema requiring airway protection; administration of icatibant after 72 h of persistent symptoms was followed by sufficient improvement to allow extubation within 36 h.[5] Additional small case series and uncontrolled reports suggest symptomatic improvement, but randomized controlled data are limited and mixed.[7]

• Acquired C1 inhibitor deficiency / acquired angioedema: Case reports describe successful treatment of angioedema attacks associated with acquired C1 inhibitor deficiency using icatibant, with relatively rapid resolution of symptoms.[6][8] Sample sizes are small and no large controlled trials have been completed.

Early human pharmacology

The human forearm vasodilation study in eight healthy men demonstrated dose‑related inhibition of intra‑arterial bradykinin‑induced vasodilation with intravenous icatibant, providing early proof of mechanism at the vascular level.[12]

Overall, the highest‑quality evidence for icatibant consists of Phase III randomized trials in HAE, with supportive open‑label and real‑world data; other indications rely primarily on uncontrolled evidence.

Clinical and research uses

Approved indications

• United States (FDA): Icatibant (Firazyr) is approved for treatment of acute attacks of hereditary angioedema in adults with C1 inhibitor deficiency (HAE type I or II).[11][13][15]
• European Union (EMA): Icatibant is approved for treatment of acute HAE attacks in adults, adolescents, and children ≥2 years of age; pediatric approvals have expanded over time based on additional studies.[11][13]

The drug is used for attacks involving cutaneous, abdominal, or laryngeal edema, including potentially life‑threatening laryngeal episodes, although airway protection remains paramount.[11][14]

Off‑label and investigational uses

• ACEI‑induced angioedema: Icatibant has been used off‑label for ACEI‑related angioedema, particularly in severe cases with airway compromise.[5][7] Reported experience includes case reports and small series; some randomized trials have produced heterogeneous results, and routine use remains an area of ongoing evaluation.

• Acquired C1 inhibitor deficiency / acquired angioedema: Case reports document successful use of icatibant when conventional therapies were limited or unavailable.[6][8] Evidence remains low‑level.

• Other kinin‑mediated conditions: Preclinical and early clinical investigations have explored bradykinin B2 receptor antagonism in cardiovascular and inflammatory settings, but icatibant’s current clinical role is largely confined to angioedema.[10][12][15]

Dosing context

Regulatory‑approved regimens and published trials consistently utilize single subcutaneous injections of 30 mg icatibant for adults with acute HAE attacks.[11][14][15]

Key dosing features reported in the literature include:

• Route and formulation: Subcutaneous injection of icatibant acetate solution, typically via a 3 mL prefilled syringe (30 mg total dose).[11][14][15]
• Frequency: Many acute HAE attacks respond to a single 30 mg dose. In clinical trials and product labeling, additional doses have been permitted after defined intervals (e.g., ≥6 hours between doses), up to a specified maximum number of doses per 24 hours, when symptoms persist or recur.[11][14][15]
• Self‑administration: Studies and real‑world reports show that appropriately trained patients can self‑administer icatibant subcutaneously during attacks, reducing time to treatment and healthcare utilization.[1][2][11]

Pediatric dosing strategies involve weight‑based or lower fixed doses, as reflected in EU labeling and pediatric trials; these differ from adult dosing and are based on limited but growing evidence.[11]

All dosing decisions, including repeat dosing and pediatric regimens, require adherence to product labeling and specialist guidance; icatibant is not indicated for prophylaxis, and long‑term preventive use has not been established.[11][15]

Safety profile

Across randomized trials and long‑term observational studies in HAE, icatibant has been generally well tolerated.[4][11][14][15]

• Local injection‑site reactions: The most common adverse events are mild to moderate, self‑limiting local reactions at the injection site (erythema, swelling, burning, pain, pruritus). These occur in a majority of treated patients and typically resolve without intervention.[4][11][14][15]

• Systemic adverse events: Other commonly reported reactions include headache, dizziness, nausea, abdominal pain, fatigue, rash, and increased transaminases or creatine phosphokinase, mostly mild and transient.[4][11][15]

• Immunogenicity: Anti‑icatibant antibodies have been infrequently reported, with no clear association with loss of efficacy or safety events in available datasets.[11]

• Cardiovascular considerations: Because endogenous bradykinin may have cardioprotective and vasodilatory effects, theoretical concerns exist that B2 receptor antagonism might adversely affect coronary blood flow or cardiac function, particularly in patients with pre‑existing ischemic heart disease.[15] Clinical evidence demonstrating significant cardiovascular harm is limited, but cautious use and monitoring in high‑risk patients are advised.[15]

• Serious adverse events: Serious treatment‑related adverse events, including anaphylaxis, have been rare in clinical trials and post‑marketing surveillance.[4][11][14] Most reported serious events were related to the underlying disease rather than the drug.

Overall, the safety profile is dominated by local injection‑site reactions, with relatively few systemic toxicities reported at therapeutic doses.

Regulatory status

Icatibant holds orphan drug designation for hereditary angioedema and is approved in multiple jurisdictions.

• United States: Firazyr (icatibant) is approved by the FDA for treatment of acute attacks of hereditary angioedema in adults with C1 inhibitor deficiency.[11][13][15] The product is supplied as a prefilled syringe for subcutaneous use. It is not approved for prophylaxis, pediatric use, or non‑HAE angioedema.

• European Union: The European Medicines Agency (EMA) has authorized icatibant for treatment of acute HAE attacks in adults, adolescents, and children aged 2 years and older.[11][13] The EU indication is broader in age range than the original US approval and reflects additional pediatric data.

• Other regions: Icatibant has been approved in Canada, Japan, and several other countries for acute HAE attacks, generally with similar on‑demand indications and subcutaneous 30 mg dosing in adults.[2][4][11]

Use of icatibant for ACEI‑induced angioedema, acquired angioedema, or other off‑label indications is not currently supported by formal regulatory approval and relies on clinician judgment and local policy, with evidence largely limited to small clinical studies and case reports.[5][6][7][8]